Premium
Novel antithrombotic agents and the risk of bleeding
Author(s) -
Van Der Linden Jan
Publication year - 2008
Publication title -
transfusion
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.045
H-Index - 132
eISSN - 1537-2995
pISSN - 0041-1132
DOI - 10.1111/j.1537-2995.2007.01576.x
Subject(s) - medicine , aprotinin , discontinuation , antithrombotic , factor viia , bypass grafting , surgery , antithrombin , population , artery , anesthesia , coagulation , heparin , environmental health , tissue factor
Many coronary patients on antiplatelet (PLT) drugs require coronary artery bypass grafting surgery under conditions that may not allow sufficient time for or warrant discontinuation of anti‐PLT treatment. Recent clinical data show that intraoperative aprotinin significantly reduces postoperative bleeding and transfusion requirements in this patient population. If surgical bleeding persists, the administration of Factor VIIa should be considered.